Elevated Plasma MMP1 and MMP9 are Associated with Abdominal Aortic Aneurysm Rupture  by Wilson, W.R.W. et al.
Eur J Vasc Endovasc Surg 35, 580e584 (2008)
doi:10.1016/j.ejvs.2007.12.004, available online at http://www.sciencedirect.com onElevated Plasma MMP1 and MMP9 are Associated with Abdominal
Aortic Aneurysm Rupture
W.R.W. Wilson,1 M. Anderton,1 E.C. Choke,2 J. Dawson,2 I.M. Loftus2 and M.M. Thompson2*
1Department of Surgery, University of Leicester, United Kingdom, and 2Department of Vascular Surgery,
St George’s Hospital Medical School, London, United Kingdom*Corre
Surger
Blacks
E-mail
1078–5Background. The role of matrix metalloproteinases (MMPs) in abdominal aortic aneurysm (AAA) formation is well
established. However the changes in plasma MMP levels with AAA rupture have not been reported. The aim of this study
was to determine circulating levels of MMPs in non-ruptured and ruptured AAA immediately prior to open repair.
Methods. Concentrations of MMPs and their endogenous tissue inhibitors (TIMPs) were quantified using ELISA in
pre-operative plasma samples from non-ruptured and ruptured AAA.
Results. MMP1 and MMP9 were elevated in the plasma of ruptured AAA versus non-ruptured AAA. A four-fold
elevation in pre-operative plasma MMP9 was associated with non-survival at 30 days from rupture surgery compared
with those surviving for greater than 30 days.
Conclusion. In conclusion, these findings support the role of MMPs in AAA pathogenesis. Elevation of MMP9 was
associated with ruptured aneurysm related 30-day mortality and may represent a survival indicator in this group.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The principal of abdominal aortic aneurysm (AAA)
treatment is the exclusion of the aneurysmal vessel
from the circulation either by open surgical repair or
more recently by endovascular means. The commit-
ment to elective surgery is not without risk and
30-day mortality following elective aneurysm repair
ranges from 2 to 6%.1,2 The mortality associated with
AAA rupture is unacceptably high with post-operative
mortality around 40%.3 Although the risk of aneurysm
rupture increases exponentially with vessel diameter,
rupture can occur in small aneurysms and the accurate
prediction of impending rupture has proved elusive.
The role of matrix metalloproteinases (MMPs) in
aneurysmdevelopment and rupture iswell described.4
However, a clear role for plasmaMMPs in disease pre-
dictionhasnot been established. Theplasma concentra-
tions of various MMPs have been reported to predict
the natural history of small AAAs.5 Furthermore, fall-
ing circulatory levels of MMPsmay indicate successfulsponding author. Prof. M. M. Thompson, Dept. of Vascular
y, 4th Floor, St. James Wing, St. George’s Hospital NHS Trust,
haw Road, London, SW17 0QT, UK.
address: matt.thompson@stgeorges.nhs.uk
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sistently high levels may indicate an endoleak.6 The
elevation of specific MMPs within the vessel wall of
a ruptured AAA has been observed7 but a change in
plasma MMP levels at the time of rupture has not
been described.
This study was the first to quantify plasma MMP
and the endogenous tissue inhibitor of MMPs
(TIMP1) in blood samples taken immediately prior to
the repair of elective and ruptured AAA. The primary
aim of this study was to determine if circulating levels
of MMPs and TIMPs reflected the clinical state of an
AAA, namely stable versus ruptured AAA. The sec-
ondary aim of this study was to observe changes in
MMP and TIMP levels associated with 30-day mortal-
ity in rupture patients.Methods
Study design
Two patient groups were studied, 52 patients with
non-ruptured AAA undergoing elective repair, and
16 patients with ruptured AAA undergoing emergency
surgery. Local research ethics committee approval forr Surgery. Published by Elsevier Ltd. All rights reserved.
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from all patients. The diameter of each ruptured AAA
was measured intra-operatively. The maximum exter-
nal diameter of each non-ruptured AAA was deter-
mined from a pre-operative computed tomogram.
Patient demographic information included age, gen-
der, smoking history (current or ex-smoker of less than
10 years versus non-smoker or ex-smoker of greater
than 10 years), presence of a cardiovascular event
(documented myocardial infarction, cerebrovascular
or peripheral vascular disease, angina requiring medi-
cation), hypertension (requiring medication), and
diabetes (requiring medication or dietary modifica-
tion). Cardiovascular medication was also recorded
(statin, beta-blocker, calcium channel-blocker, acetyl-
choline-esterase inhibitor and non-steroidal anti-
inflammatory). Outcome data included 30-day all-cause
mortality in the rupture cohort.Sample collection
Blood samples were obtained immediately pre-
operative, by venepuncture, to tubes containing
sodium ethylenediamine tetra-acetate. Separation of
cellular and plasma components was achieved
with centrifugation (3000 g for 20 mins); the plasma
was decanted and stored at 80 C.MMP quantification
Enzyme-linked immunosorbent assay kits (Amersham
Pharmacia Biotech, Buckinghamshire, UK) were used
to quantify the following from each plasma sample;
MMP1, MMP2, MMP3, MMP9 and TIMP1. All samples
were run induplicate, and anaverage obtained. Thefinal
concentration of eachMMP and TIMPwas expressed as
nanograms of target protein per millilitre of plasma.Table 1. Characteristics of patients with non-ruptured and ruptured
Patient Characteristics Non-Ruptured AAA (n¼ 52)
Age 72 (þ/1.0) yrs
AAA size 6.0 (5.7e6.5)
Gender Distribution 46 males (88%)
Cardiovascular Event 18 (35%)
Hypertension 26 (50%)
Smoking History 42 (81%)
Diabetes 5 (9.6%)
Statin 12 (23%)
Beta-Blocker 11 (21%)
Ca2þ Channel Blocker 12 (23%)
ACEI 14 (27%)
NSAID 20 (38%)
(Comparison used independent t-test (*) with group mean and stan
and interquartile range in cm, and Fisher’s Exact Test; acetylcholines
p< 0.02).Statistical analysis
Statistical analysis used GraphPad Prism 5. Discrete
variables were presented as numbers and percentages
and compared using Fisher’s exact test. The continuous
variable of age was normally distributed, presented as
a mean (and standard error) and compared using the
independent t-test. Other continuous variables were
non-normally distributed, reported as a median and
interquartile range (AAA diameter, MMP and TIMP
levels) and compared using the Mann-Whitney U-
test. Correlations used the Spearman’s test, statistical
significance was assumed at the p< 0.02 level.Results
Patient demographics
The clinical features of the non-ruptured and rup-
tured AAA patient cohorts are described in Table 1.
Median AAA diameter was greater in ruptured than
non-ruptured AAA. There were no other differences
in the characteristics of the study cohorts.Plasma MMP and TIMP concentrations: ruptured
AAA versus non-ruptured AAA
Table 2 details plasma levels if MMPs and TIMPs from
ruptured and non-ruptured AAA. There were no sta-
tistical differences in the concentrations of MMP2,
MMP3 or TIMP1. In contrast, the concentrations of
MMP1 and MMP9 were significantly elevated in the
plasma of ruptured AAA compared with non-ruptured
AAA (MMP1, 20.2 ng/ml [16.1e28.7] vs. 8.9 ng/ml
[5.6e15.7], p< 0.0001; MMP9, 59.1 ng/ml [20.8e123.7]
vs. 17.5 ng/ml [10.3e34.2], p¼ 0.006).abdominal aortic aneurysms (AAA)
Ruptured AAA (n¼ 16) p-value
70 (þ/1.2) yrs 0.289*
10 (7.5e11) <0.001y
13 males (81%) 1.0
3 (19%) 0.229
7 (44%) 0.778
12 (75%) 0.726
0 (0%) 0.330
1 (6%) 0.273
1 (6%) 0.268
5 (31%) 0.523
1 (6%) 0.094
3 (19%) 0.248
dard error in years, Mann-Whitney U-test (y) with group median
terase inhibitor (ACEI), non-steroidal anti-inflammatory (NSAID),
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Table 2. Comparison of plasma matrix metalloproteinase (MMP)
and tissue inhibitor of MMP (TIMP) concentrations in non-
ruptured abdominal aortic aneurysms (AAA) and ruptured AAA
Enzyme
Group
Non-Ruptured AAA
(n¼ 52)
Ruptured AAA
(n¼ 16)
p-value
MMP-1 8.90
(5.57e15.69)
20.18
(16.09e28.68)
<0.001*
MMP-2 42.14
(28.71e68.69)
51.58
(42.23e68.44)
0.325
MMP-3 9.43
(6.99e13.54)
8.36
(5.91e11.44)
0.268
MMP-9 17.54
(10.30e34.24)
59.11
(20.82e123.70)
0.006*
TIMP-1 460.80
(199.80e611.00)
229.50
(192.60e492.20)
0.456
(Concentrations shown as median and interquartile range, units
ng/ml, comparison used Mann Whitney-U test, p< 0.02, *¼
significance).
Table 4. Correlation of plasma matrix metalloproteinase (MMP)
and tissue inhibitor of MMP (TIMP) concentrations in non-
ruptured abdominal aortic aneurysms (AAA) and ruptured AAA
Enzyme
Group
Correlation between AAA
diameter and enzyme
concentration
p-value
Non-ruptured AAA
MMP-1 0.147 (0.142e0.414) 0.302
MMP-2 0.126 (0.163e0.395) 0.379
MMP-3 0.004 (0.287e0.280) 0.977
MMP-9 0.196 (0.092e0.454) 0.167
TIMP-1 0.069 (0.346e0.218) 0.626
Ruptured AAA
MMP-1 0.576 (0.019e0.861) 0.040
MMP-2 0.183 (0.424e0.677) 0.549
MMP-3 0.271 (0.346e0.724) 0.371
MMP-9 0.390 (0.222e0.782) 0.187
TIMP-1 0.286 (0.732e0.331) 0.344
(Comparison used Spearman Correlation, p< 0.02).
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Comparison of MMP and TIMP levels in ruptured
AAAwith respect to 30-daymortality (Table 3) demon-
strated significantly higher levels of MMP9 immedi-
ately pre-operatively in the plasma of non-survivors
at 30 days from rupture surgery compared to survivors
beyond 30 days (131.9 ng/ml [75.5e191.8] versus
32.2 ng/ml [5.9e129.5], p¼ 0.017). Furthermore,
MMP1 was higher and TIMP1 lower in non-survivors
of rupture though neither comparison reached
significance.
Plasma MMP and TIMP concentrations: correlation
with aneurysm size
There were no significant correlations between AAA
diameter and enzyme concentrations within the non-
ruptured and ruptured cohorts (Table 4). The correlationTable 3. Comparison of plasma matrix metalloproteinase (MMP)
and tissue inhibitor of MMP (TIMP) concentrations in ruptured
abdominal aortic aneurysms (AAA) surviving greater than 30
days versus non-survivors at 30 days
Enzyme
Group
Ruptured AAA
non-survivors
at 30 days (n¼ 5)
Ruptured AAA
survivors beyond
30 days (n¼ 11)
p-value
MMP-1 26.46
(17.76e50.93)
17.76
(5.43e55.65)
0.079
MMP-2 52.43
(43.39e70.19)
51.12
(26.76e72.75)
0.428
MMP-3 9.61
(4.78e30.25)
7.77
(2.13e73.85)
0.777
MMP-9 131.90
(75.49e191.80)
32.23
(5.86e129.5)
0.017*
TIMP-1 189.91
(82.81e310.12)
232.84
(187.24e7458.63)
0.113
(Concentrations shown as median and interquartile range, units
ng/ml, comparison used ManneWhitney-U test, p< 0.02, *¼
significance).
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significance but importantly the correlation with non-
ruptured AAA diameter was non-significant. The non-
significance of these correlations indicated that elevated
plasma MMP1 and MMP9 were associated with AAA
rupture rather than AAA diameter.
Discussion
Observational studies support the association be-
tween elevated matrix metalloproteinase expression
at vascular tissue level and the presence of aneurys-
mal aortic dilatation and rupture4,7 Gene knockout
models confirm the critical role of MMP9 in the gene-
sis of the abdominal aortic aneurysm. The MMP9 de-
ficient genotype is unable to develop an aneurysmal
phenotype following chemical stimulus. Macrophage
transfection of the MMP9 gene results in restoration
of MMP9 protein expression and subsequently the
development of the aneurysmal phenotype.8
Circulating MMP levels in aneurysm patients are
less comprehensively understood however, elevation
of plasma MMP levels in the presence of an abdomi-
nal aortic aneurysm is described. Plasma levels of
MMP9 are higher in AAA patients than in normal
or athero-occlusive controls.9,10 Indeed plasma
MMP9 is significantly associated with the size and
expansion of smaller AAA, of 3e5 cm in diameter.5
Interestingly, plasma MMP-9 and MMP-3 levels fall
markedly after successful open and endovascular
repair,10 but remained significantly elevated in a sub-
group of patients with endoleak.6
Our study observed the significant elevation of
plasma MMP1 and MMP9 in ruptured AAA relative
to a cohort of stable elective AAA, in blood samples
taken immediately prior to open repair. The changes
in plasma MMP1 and MMP9 levels were not
583Plasma MMP1 and MMP9: Association with AAA Ruptureassociated with a reciprocal elevation in TIMP1. Inter-
estingly, within the cohort of ruptured AAA, patients
who deceased within or at 30 days following surgery
had pre-operative plasma MMP9 levels 4-fold higher
than those who survived beyond 30 days.
Unlike tissue MMP levels, the correlation of plasma
levels of MMP’s with aneurysm diameter has not been
widely reported. A weakly negative correlation be-
tween tissue levels of MMP9 and increasing AAA
diameter has been suggested.7,11 In our study, plasma
MMP levels did not correlate significantly with AAA
diameter. Although plasma MMP1 levels did ap-
proach significance in the ruptured group, it is impor-
tant to note the correlations for both MMP1 and
MMP9 with non-ruptured AAA diameter were non-
significant. Therefore, the observed difference in
aneurysm size between non-ruptured and ruptured
aneurysms did not confound our analysis.
In the stable aneurysmal state, plasma MMPs prob-
ably originate directly from the site of vascular abnor-
mality i.e. directly from the aneurysm wall and/or the
lining thrombus. This is supported by the significant
fall of circulating MMP levels following exclusion of
the aneurysmal sac from the systemic circulation.10,12
Within the aneurysmal wall various candidate cells
are proposed as the source of MMP expression. These
including native mesenchymal cells (fibroblasts and
smooth muscle cells) and infiltrating inflammatory
cells.7,13,14
This study did not establish whether the elevation of
plasma MMP1 and MMP9, seen in ruptured AAA, was
part of a gradual phenomenon, which predated the rup-
ture event, or a rapid change occurring after the point of
vessel rupture. A gradual pre-rupture elevation of
plasmaMMP levels may suggest the source of increased
MMP production was the aneurysm itself. An acute
post-rupture elevation in plasma MMP1 and MMP9
levels could also result from an increase in MMP pro-
duction from the site of aneurysm rupture or originate
from the systemic inflammatory changes that ensue
following aneurysm rupture.
Previous work indicates that MMP9 is elevated in
ruptured AAA however, upregulation is only ob-
served at the site of aneurysm rupture and not globally
in the ruptured vessel.7 Of note, increased circulating
MMP9 is observed following other acute cardiovascu-
lar events including carotid plaque instability, acute
coronary syndrome and myocardial infarction.15,16
During the acute stage of a myocardial infarct, the re-
lease of MMP9 is considered to originate mainly from
unstable plaque and the myocardium.16
Alternatively, since a systemic inflammatory re-
sponse normally follows aneurysm rupture, it is likely
that release from cells within the systemicinflammatory cascade accounts for some if not all of
the circulating MMP9 and MMP1 after the rupture
event. The elevation of circulating MMP9 is described
in other critically ill patients.17,18 Hoffam et al., de-
scribed higher circulating MMP9 levels in septic pa-
tients relative to non-septic patients, yet MMP2 levels
were similar.17 Yassen et al., reported in a smaller study,
the elevation of MMP9 in critically ill patients (both
septic and non-septic) relative to normal controls.18
Our observation of the pre-operative four-fold ele-
vation in plasmaMMP9 in non-surviving patients ver-
sus surviving rupture patients at 30 days, suggested
the process following aneurysm rupture was more ag-
gressive in the non-survivors. Elevation of MMP9 in
non-surviving patients following a physiological insult
has been reported though not exclusively in ruptured
aneurysm patients. Nakamura et al. observed a greater
elevation of MMP9 at plasma protein and monocyte
mRNA levels in non-surviving versus surviving septic
patients.19
We failed to observe significant differences in TIMP1
concentrations in stable versus ruptured aneurysms or
30-day survivors versus non-survivors. However, other
reports indicated that TIMP1 was elevated in non-sur-
vivors of sepsis compared with survivors and TIMP1
was suggested as a survival indicator in this cohort
of patients.17 However, the equivalence in our findings
mirrors the findings from other aneurysm studies re-
porting tissue levels in stable versus ruptured
AAA7,11 and equivalence of circulating levels despite
expansion.5 This sustains the hypothesis that elevation
of MMP levels and the failure to mount a reciprocal
TIMP response results in increased proteolytic activity.
In conclusion, this study supports the central role of
MMPs in AAA pathogenesis. Elevated plasma MMP9
is associated with the presence of an aneurysm and
the expansion of small aneurysms.5 Here we demon-
strate the further elevation of plasma MMP9 and
MMP1 immediately following aneurysm rupture.
Though the study cannot indicate if these are acute or
chronic changes, MMP9 is significantly higher in non-
survivors than survivors of aneurysm rupture and
may represent a survival indicator in this patient group.References
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